Renal Cancer
Oncology
4
Pipeline Programs
7
Companies
6
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
2100%
+ 8 programs with unclassified modality
Competitive Landscape
7 companies ranked by most advanced pipeline stage
Bristol Myers SquibbPRINCETON, NJ
2 programs1
IpilimumabPhase 2Monoclonal Antibody1 trial
National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)N/A
Active Trials
HistoSonicsMI - Ann Arbor
2 programsHistoSonics Edison SystemN/A1 trial
HistoSonics Investigational SystemN/A1 trial
Active Trials
M&
Merck & Co.RAHWAY, NJ
1 programNational PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)N/A
IpsenChina - Tianjin
1 programNational PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)N/A
PfizerNEW YORK, NY
1 programNational PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Bristol Myers SquibbIpilimumab
GenentechBevacizumab
NovartisBEZ235
HistoSonicsHistoSonics Edison System
HistoSonicsHistoSonics Investigational System
PfizerNational PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)
Clinical Trials (6)
Total enrollment: 2,301 patients across 6 trials
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
Start: Oct 2017Est. completion: Jun 202685 patients
Phase 2Active Not Recruiting
High-dose Bevacizumab in Advanced Renal Carcinoma Patients
Start: Feb 2007Est. completion: Sep 2013119 patients
Phase 2Completed
BEZ235 in Patients With Advanced Renal Cell Carcinoma (RCC)
Start: Oct 2011Est. completion: Apr 201410 patients
Phase 1/2Terminated
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)
Start: Jan 2024Est. completion: Jul 203067 patients
N/AActive Not Recruiting
The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using Histotripsy
Start: Mar 2023Est. completion: Jun 202520 patients
N/ACompleted
National PROspective Infrastructure for Renal Cell Carcinoma (PRO-RCC)
Start: Jan 2023Est. completion: Jan 20302,000 patients
N/ARecruiting
Related Jobs in Oncology
Senior Research Associate, Immuno-Oncology
SystImmune
16m ago
$60K - $85K/yr
Research Associate I/II, Immuno-Oncology
SystImmune
16m ago
Office Administrator
SystImmune
16m ago
$60K - $80K/yr
Scientist/Sr Scientist
TwoStep Therapeutics
San Carlos
26m ago
Working Student Office Management Support (m/f/d)
Mindpeak
Hamburg
30m ago
Senior Medical Project Manager (m/f/d)
Mindpeak
Hamburg
30m ago
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 2,301 patients
7 companies competing in this space